Inhibition of the antiangiogenic factor soluble Fms-like tyrosine kinase-1 (sFlt-1) might improve renal transplantation outcomes, say researchers. Chapal et al. found that during the first week after transplantation, sFlt-1 levels increased 2–3-fold in 136 renal transplant recipients. The increase in sFlt-1 levels was greater in recipients of deceased-donor grafts than in recipients of living-donor grafts, and peak plasma sFlt-1 levels ≥250 pg/ml were associated with a 2.5-fold increase in the risk of delayed graft function, and with early loss of peritubular capillaries.